# Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

> **NCT07410494** · PHASE1,PHASE2 · RECRUITING · sponsor: **Essen Biotech** · enrollment: 85 (estimated)

## Conditions studied

- Cancer
- Breast Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (Locally Advanced or Metastatic)
- Prostate Cancer - Recurrent
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Ovarian Cancer
- Glioblastoma
- Melanoma (Skin Cancer)
- Acute Myeloid Leukemia (AML)
- Non Hodgkin Lymphoma
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
- Liver Cancer

## Interventions

- **BIOLOGICAL:** EB-SELECT Single-Target CAR-NK Cells
- **BIOLOGICAL:** Dual-Target Antigen-Selected CAR-NK

## Key facts

- **NCT ID:** NCT07410494
- **Lead sponsor:** Essen Biotech
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-12-28
- **Final completion:** 2028-12-28
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07410494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07410494, "Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07410494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*